PuSH - Publikationsserver des Helmholtz Zentrums München: Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Lehrke, M.* ; Becker, A.* ; Greif, M.* ; Stark, R.G. ; Laubender, R.P. ; von Ziegler, F.* ; Lebherz, C.* ; Tittus, J.* ; Reiser, M.* ; Becker, C. ; Göke, B.* ; Leber, A.W.* ; Parhofer, K.G.* ; Broedl, U.C.*

Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.

Eur. J. Endocrinol. 161, 339-344 (2009)

DOI

PMC

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Objectives: Chemerin is a recently discovered adipokine that regulates adipocyte differentiation and modulates chemotaxis and activation of dendritic cells and macrophages. Given the convergence of adipocyte and macrophage function, chemerin may provide an interesting link between obesity, inflammation and atherosclerosis in humans. We sought to examine the relationship of 1) chemerin and markers of inflammation, 2) chemerin and components of the metabolic syndrome, and 3) chemerin and coronary atherosclerotic plaque burden and morphology. Design: Serum chemerin levels were determined in 303 patients with stable typical or atypical chest pain who underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic plaques were classified as calcified, mixed or non-calcified. Results: Chemerin levels were highly correlated with hsCRP (r=0.44, p<0.0001), IL-6 (r=0.18, p=0.002), TNF-{alpha} (r=0.24, p<0.0001), resistin (r=0.28, p<0.0001) and leptin (r=0.36, p<0.0001) concentrations. Furthermore, chemerin was associated with components of the metabolic syndrome including BMI (r=0.23, p=0.0002), triglycerides (r=0.29, p<0.0001), HDL-C (r=-0.18, p=0.003) and hypertension (p<0.0001). In bivariate analysis, chemerin levels weakly correlated with coronary plaque burden (r=0.16, p=0.006) and the number of non-calcified plaques (r=0.14, p=0.02). These associations, however, were lost after adjusting for established cardiovascular risk factors (OR 1.17, 95%CI 0.97 to 1.41, p=0.11 for coronary plaque burden; OR 1.06, 95%CI 0.96 to 1.17, p=0.22 for non-calcified plaques). Conclusions: Chemerin is strongly associated with markers of inflammation and components of the metabolic syndrome. Chemerin, however, does not predict coronary atherosclerosis.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

3.791

1.520

167

249